Evaluation of PET/CT imaging with [89Zr]Zr-DFO-girentuximab: a phase 1 clinical study in Japanese patients with renal cell carcinoma (Zirdac-JP).

Noboru NakaigawaHisashi HasumiDaisuke UtsunomiyaKeisuke YoshidaYoshinobu IshiwataTakashi OkaColin HaywardKazuhide Makiyama

Published in: Japanese journal of clinical oncology (2024)

This study demonstrates that [89Zr]Zr-DFO-girentuximab administered to Japanese patients with suspected RCC has a favorable safety profile and is well tolerated and has a similar dosimetry profile to previously studied populations.

Keyphrases

pet ct
pet imaging
renal cell carcinoma
positron emission tomography
high resolution
computed tomography
clinical trial
genetic diversity
solid state